Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
In-depth Analysis of Heart Failure Drugs Market Industry Landscape
The heart failure drugs market is characterized by a dynamic landscape of innovation, with major players continuously introducing new products and conducting clinical trials to address the unmet needs of patients battling heart failure. These advancements are propelling the market's growth and offering hope for improved patient outcomes. In October 2019, AstraZeneca received the green light from the US Food and Drug Administration (FDA) for Farmiga (dapagliflozin), a medication that effectively reduces the risk of hospitalization for heart failure (hHF) in adults with type-2 diabetes (T2D).
This approval signifies a significant step forward in managing heart failure in a population at heightened risk of the condition. Further demonstrating the industry's commitment to innovation, Ono Pharmaceutical, a leading pharmaceutical company in Japan, launched Coralan (ivabradine hydrochloride) in September 2019 for the treatment of individuals with chronic heart failure (CHF). This medication provides a valuable therapeutic option for managing the debilitating symptoms of CHF and improving quality of life for affected patients. Amgen, in collaboration with Cytokinetics, is actively developing Omecamtiv macabrely, a selective cardiac myosin activator, for the treatment of heart failure with reduced ejection fraction (HFrEF).
This promising therapy holds the potential to address a significant unmet need in the treatment of HFrEF, a particularly challenging form of heart failure. In April 2015, Amgen secured FDA approval for Coplanar (ivabradine), an oral medication designed to reduce the risk of hospitalization for worsening heart failure in patients with chronic heart failure and an ejection fraction of less than 35%. This approval further underscores Amgen's commitment to developing innovative therapies that improve patient outcomes in the management of heart failure.
These recent product launches and clinical trials exemplify the dynamic and innovative nature of the heart failure drugs market. As major players continue to invest in research and development, the pipeline of promising therapies is expanding, offering renewed hope for patients battling heart failure and paving the way for improved treatment options and patient outcomes.
Covered Aspects:| Report Attribute/Metric | Details |
|---|---|
| Segment Outlook | Type, End User, and Region |
Heart Failure Drugs Market Highlights:
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
